<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess therapeutic and prophylactic effect of large-dose cerebrolysin (15 ml/day for 28 days) in hypertensive and atherosclerotic patients with <z:e sem="disease" ids="C0009241" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study </plain></SENT>
<SENT sid="2" pm="."><plain>The effect was stated by clinical status, neuropsychological and neurophysiological data </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In mild disturbances of cognitive functions in patients with arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and <z:e sem="disease" ids="C0233629" disease_type="Mental or Behavioral Dysfunction" abbrv="">thinking</z:e> which persist for at least a year after the course </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical data agree with positive trend in neurophysiological parameters of cognitive component of the response of evoked potentials P-300 </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: A course of 28-day annual treatment with cerebrolysin (15 ml/day) of patients with mild defects of cognitive functions stabilizes the process, leads to regression of <z:e sem="disease" ids="C0009241" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive disorders</z:e> predicting vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>